Veloxis Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VELOXIS PHARMS INC, and what generic alternatives to VELOXIS PHARMS INC drugs are available?
VELOXIS PHARMS INC has one approved drug.
There are twenty-three US patents protecting VELOXIS PHARMS INC drugs.
There are forty-nine patent family members on VELOXIS PHARMS INC drugs in twenty-four countries.
Summary for Veloxis Pharms Inc
| International Patents: | 49 |
| US Patents: | 23 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Veloxis Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | 8,623,411 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | 11,123,331 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | 8,889,186 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | RX | Yes | No | 9,757,362 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | RX | Yes | Yes | 8,486,993 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | RX | Yes | Yes | 7,994,214 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | RX | Yes | Yes | 8,591,946 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Veloxis Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | 9,763,920 | ⤷ Subscribe |
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | 8,586,084 | ⤷ Subscribe |
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | 8,617,599 | ⤷ Subscribe |
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | 8,591,946 | ⤷ Subscribe |
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | 7,994,214 | ⤷ Subscribe |
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | 8,486,993 | ⤷ Subscribe |
| Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | 10,548,880 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Veloxis Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 027869 | ⤷ Subscribe |
| Eurasian Patent Organization | 201390412 | ⤷ Subscribe |
| Denmark | 2575769 | ⤷ Subscribe |
| Denmark | 2167033 | ⤷ Subscribe |
| Austria | 473003 | ⤷ Subscribe |
| European Patent Office | 2167033 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2005020994 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
